Presentation on theme: "GE Healthcare AS Medical Diagnostics Norway"— Presentation transcript:
1 GE Healthcare AS Medical Diagnostics Norway Who are we today?What are our success criteria?
2 Who we are: GE business segments AviationEnergyEnterpriseSolutionsWaterOil & GasCommercialFinanceGE MoneyCorporateTreasuryTransportationHealthcareTechnologyInfrastructureGE CapitalNBC UniversalGE is Imagination at Work - a diversified technology, media and financial services company focused on solving some of the world's toughest problems. With products and services ranging from aircraft engines, power generation, water processing and security technology to medical imaging, business and consumer financing, media content and industrial products, we serve customers in more than 100 countries and employ more than 320,000 people worldwide.GE Commercial Finance Loans, operating leases, financing programs, commercial insurance, and an array of other products and services aimed at enabling business worldwide to grow. GE Money A leading provider, under the GE Money brand, of credit services to consumers, retailers and automotive dealers around the world. GE Healthcare Helping healthcare professionals world-wide, transform patient care through products and services designed to help predict, diagnose, access information and treat disease earlier and more effectively.GE IndustrialProviding a broad range of products and services throughout the world, including appliances and lighting; plastics and silicones products; and equipment services.GE InfrastructureOne of the world's leading providers of aviation, energy, oil and gas, rail and water process technologies.NBC UniversalOne of the world's leading media and entertainment companies in the development, production and marketing of entertainment, news and information to a global audience
3 Broad solutions for healthcare Medical DiagnosticsElectronicmedical recordsDiagnostic imaging & SurgeryDiscovery toolsIntegrated admin. & clinicalClinical SystemsPicture Archiving System (PACS)Protein & cell sciencesClinical tissue biomarkersBroad-basedDiagnosticsLifeSciencesInformationTechnologyGE’s product offerings go deep and wide. From Diagnostic imaging products across the standard modalities and new emerging modalities like Molecular Imaging, to interventional, surgical guidance, bio pharmaceutical production and integrated IT solutions
4 GE Healthcare $17B global business unit of GE $1B+/year in R&D investmentOver 2,000 research scientistsNearly 1,000 PhDsMultiple disciplines45 different nationalitiesemployeesGE Healthcare provides transformational medical technologies that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention.Headquartered in the United Kingdom, GE Healthcare is a $15 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 44,000 people committed to serving healthcare professionals and their patients in more than 100 countries. There’s more information about GE Healthcare on our website at
5 Medical Diagnostics (~4500 employees) The only Pharmaceutical unit in GEWorld leader in contrast agents and nuclear medicine products for diagnostic imaging across all modalities.
6 GE Healthcare AS – Norwegian branch of Medical Diagnostics Milestones Pharmacist Morten NyegaardFounder of Nyegaard & Co,later Nycomed, in 1874Nycomed’s firstX-ray contrastmedium, a copyprep. reg.1934Nycomed develops world’s firstnon-ionic X-ray contrast medium in collaboration with ProfessorTorsten Almén of Lund, SwedenOmnipaque, 2nd generation non-ionicX-ray contrast medium, for many yearsranked among the top 10 pharma-ceutical products sold world-wide.The exceptional R&D environment that has emerged in Norway since will continue to play an important role in the development of new products for diagnosis, treatment and prevention of disease. This position was continued with the merger between Nycomed and Amersham International in further strengthened under GE Healthcare from 2004
7 GE Healthcare AS Lindesnes site Oslo site (Primary manuf. 350 employees)Oslo site(Sec. manuf., R&D, 650 employees)Total revenues (incl exports): $ 1,0 billionIn market sales: $15,5 millionR&D 55 $ (ex 5.11) 136’ $ (08’) ( approx. 1 mill $ 09’)approx. 200 employeesGEHC total no of employees: Largest Pharma player in Norway
9 So what’s makes a success? (I) Key competences – focusDecisiveness (privately owned at the time)Available fundingThe right product area – niche(?)The right product opportunity - IPRKey competence - develop
10 So what’s makes a success? (II) Right strategy (build from strength)Leverage partnerships (Schering/Daiichi/Sterling) & local strengthTransition to own presence (Schering-Sterling)Focus on core competencies (CM…)Continuous improvements (Lindesnes/primary production – retain competitiveness)Long term R&D strategy and continuous investments (build capacity + feed pipeline)Business Dvlp – M&AX
11 Predict & Prevent Disease … The Future … Molecular MedicineMolecular TherapeuticsMolecular ImagingMolecular DiagnosticsPredictGene AssayMolecular DiagnosticsPinpointImagingImaging, IVDTrack andVerifyMolecular ImagingPrevent/TreatMolecular TherapeuticsDetectProteinIn Vitro(IVD)Let me try and give you an example in Alzheimer disease:Affects 4 million people, cost $10B not to mention the impact on the families of those afflicted.Let’s walk through the modelPredict - Gene assays, genetic predispositionDetect - exposing disease before the symptoms present … Protein expressionPinpoint - Immediately you want where is it and how much?Personalize - understanding your disease dictates the treatment, not the average.Treat - there are new types of treatments being developed to interrupt the pathway of disease …Track - lastly you want to know in days not months if the treatment is working … back to imagingorImaging and Diagnostics that will:assess risk earlier to intervene with preventive measuresdiagnose earlier to intervene and stop chronic disease in its tracksDiagnose more specifically and understand the patient better to select the right therapyDeliver therapy, Monitor therapy delivery, and follow-up to measure efficacy
12 Molecular Medicine Diagnose and treat before symptoms appear Provide treatments tailored to individual’s genetic makeupFocusing on cancer, heart disease and Alzheimer'sCollaborating with leading pharmaceutical companies and medical researchersGE in best position to grow and leverageImagine that a life-threatening disease is detected before symptoms appear, therapeutic drugs are seen hitting their target instantaneously, therapeutic efficacy is measured in hours instead of months, or life-saving drugs tailored to your genetic make-up and disease variant get to market years faster than possible today. This is the promise of molecular imaging.Through research being done on nuclear medicine, PET, and MR systems, to name a few, GE Global Research Center researchers -- in partnership with several pharmaceutical companies and GE Healthcare customers & clinicans -- will soon discover how diagnosis and treatment decisions can be made at the cellular level. Through genomic information from the Human Genome Project, doctors eventually will know a person's predisposition for disease, identify markers of early, aggressive disease, and prescribe a therapy targeted to prevent it years before symptoms even occur.GE Healthcare is now playing a key role in pre-clinical molecular medicine research and paving the road to the promise of molecular imaging with our exclusive eXplore series micro imaging systems for in vitro and in vivo scanning. The eXplore series use rapid, full-volume imaging acquisition geometries to maximize scanning efficiency and provide isotropic resolution of in vitro and in vivo studies with minimal dose. eXplore applications include vascular and bone imaging, angiogenesis, phenotyping and anatomical registration of molecular imaging data.
16 *Includes costs of failed compounds What is Pharma?TherapeuticsDiagnostics$650B global market$500MM - $1B sales per yearHighly regulated industry from development through marketingGeneral patent life ~ 20 yrsAverage drug development 10 – 15 yrs at a cost of greater than $1B*Generally thought of as encompassing therapeutic drugs, both branded and genericChronic administration$7B global marketSub-segment of the pharmaceutical industry (“specialty pharma”)$50 - $200MM sales per yearDrugs used to aid in diagnostic imaging procedures that highlight organs, tissues and processes in the bodyAcute administrationOnly 2 products approved in past 10 yearsPOS ranges from 16% phase 1 to 50% phase 3*Includes costs of failed compounds
17 Fra Nyegaard & Co til GE Healthcare Morten Nyegaard, cand pharmNyegaard & Co (Nyco)1986 Nycomed AS1992 Nycomed Imaging AS1997 Nycomed Amersham Imaging ASAmersham Health AS2004 GE Healthcare